GLP1R and type 2 diabetes mellitus: Although two GLP-1 receptor agonists, once-daily liraglutide [3] and once-weekly semaglutide [4], have been shown to reduce cardiovascular (CV) events in patients with type 2 diabetes at high CV risk, four CV outcome trials that evaluated the once-daily DPP-4i agents saxagliptin [5], alogliptin [6], sitagliptin [7, 8], and linagliptin [9, 10] versus placebo showed no impact on CV death, myocardial infarction (MI), or stroke outcomes.